Skip to content

Ankyrin repeat domain-containing protein 31 (ANKRD31)

Homo sapiens — UniProt Q8N7Z5

Gene: ANKRD31Homo sapiensSwissProt reviewed

Data last refreshed: (UniProt release unknown)

Key facts

Ankyrin repeat domain-containing protein 31 (ANKRD31) is a protein from Homo sapiens identified by UniProt accession Q8N7Z5, 1873 residues long. MolForge cross-references it against 0 known binders and 120 disease associations.

  • UniProt accession: Q8N7Z5; gene symbol ANKRD31.
  • Organism: Homo sapiens.
  • Length: 1873 amino acids.
  • Top disease associations (Open Targets): genetic non-acquired premature ovarian failure, low density lipoprotein cholesterol measurement and apolipoprotein B measurement.
  • 3D structure: AlphaFold model available.

Target properties

Protein nameAnkyrin repeat domain-containing protein 31
UniProt accessionQ8N7Z5
GeneANKRD31
OrganismHomo sapiens
Length1873 residues
Molecular weight—
EC numbers—
Target class—
Subcellular location—
Keywords—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tierMEDIUM
Druggability score—
Pocket score—
Max clinical phase—

Disease associations (120)

Diseases linked to this target (Open Targets).

  • genetic non-acquired premature ovarian failure · score 0.43
  • low density lipoprotein cholesterol measurement · score 0.36
  • apolipoprotein B measurement · score 0.34
  • neurodegenerative disease · score 0.29
  • Alzheimer disease · score 0.28
  • total cholesterol measurement · score 0.24
  • protein measurement · score 0.15
  • drug use measurement · score 0.12
  • azoospermia · score 0.10
  • spermatogenic failure 63 · score 0.09

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

StructureSourceMethodMean pLDDTResolution (Å)
AF-Q8N7Z5-F1alphafoldPREDICTED43.09—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q8N7Z5.

Amino-acid sequence (1873 residues)

MEEGVQAPDW DSDETVIEGS VTESDLEEKE LPWRRLLFDQ DASLKSEFSL HPDTRGMCKG MPSPEIQLGF KLREDLQEQM NKNKMMPVLS EDTILQSQDE TERNQALLQT RKNCSMFIGS FRQSGLSLNH QNIEGPEAES PEVLPHIEKE LSEGRDSPEV SLLSGTAITV SDTVAVKETS LVEPEKILAA PNTFFEPRKE VTMTMTSEET KDEESSLETF VSALESLLTS PESTQEERLF ELVSDFDRKE LMNPLSDSLS SISIPLNSWS ACHRDLLEDA KDDALPAELL EALNTLSEAK VETICHRKEG GSSLIARNEC LEVEFNTSQT NEDCTQIAET LQDPNPSGLQ TLAHQNITSC EPLSNKRNSN SVTNSSDQET ACVLRRSSRL EKLKVSRDAK YSDHMYKMPE KILPKILGCE DLTNNNSSAQ NFRMQDPALM IDGKEKNMHS ARFKNGKQIR KNEQFSGKKE KMKVNKISLH SINRRNIFGE NLVYKAALHD DADLVHHCIK KGGNVNQPSY AGWTALHEAS VGGFYRTASE LLKGGADVNI KGLYQITPLH DAVMNGHYKV AELLLLNGAD PLFRNDDGKC ALDEAKDLCM KRLLERYIPK HQKCLTSAQR SSIDPLDIED VYQHKKPKFS SKSHIWHVYN ENSNRQKLEH VKVNKGSKAS LFINKEDVYE YYQKDPKNTK FGKSKHKQST LDQIYSTGLR KGNLHNVKDP NTNVPKGIGR RKTQHKRTQV DDVDCNPRKI LAVSPSRRIN RLVTYQQHIP ETHNDLPEEL CEPSSLTLSS LRNGLDSSTE ACSVSKEKHI QNLDLSDSQE VQCLELESVD QTEAVSFPGL LLHKEIKLPV VTTDKQPHTL QEQHHVLYKS HENSNLVPKD ERFNKWENSF LSFVKENSDN DDDDDCSTSE KAITSKKVLC STGGKKHYNF KENLTNKKEM GFQQFLLSED HLSQENELKA VSLTTLPEQE AVNFSYSDNA VISEHVANYE QCIFGPSFDH SNGNPEQNSL ACMRTLLTHE ASKLTNHVEL FKKPQDYIPR APTFLMNQTD THIVEKMAKN CDTERNYIDR DQKIIYSNEP LSIVAHSQVI ETTKVEKRRQ NHLESETIHN IDSHSTDNMS KELANISKLS QREKKEISHK PGMKAGRINK RNARGESQLH LAVRRGNLPL VKALIESGAD VNLNDNAGWT PLHEASNEGS IDIIVELLKA GAKVNCENID GILPLHDAVA NNHLKAAEIL LQNGANPNQK DQKQKSALDE ADDEKMKELL RSYGAIETVN RDESDAIVNE KIPAVRSKRH KQCFCDDGKT IDSSSLSHQE RSRESLSVHQ TLSAILQDIE EKQEYLLEFE IRNPEDAEQY IEKMLKIKKI MDNVLAKQKA ERDDLAKKYR VSIESFKHGA LREQLANLAA RQKSLLVVAK KQKKISLKIQ NCRNVTSLPC LSLRKLPPRS EISSEKDSQE LTSLENLEHP QSGSLSPVSG SMQETQLSLE TWNYSQNTNI CLNSEAVRRG EFSGNDMNSK QNGSDCTLDG FPKSRHSDGT EKNKLPSQPV AFIGQTEYSQ KENDLTEATD KDHEFYVSSP VIGKLNISET ASVLAENAAH PSNIICDQDL SNYDPKRGNR KTSSQQSPTG ASESLAHQGI AVLGSDTVHQ MKPYLKKSVS VVPCADDSQI SSSSGSGQQD TIKKALNYST APKKKCIQIK DLILLGRINP GNNILEFKTQ ETTHKASILL NGKLKVESGQ IYKNPVTWLK DLLGGNSYVT WNYAWSKVTY LGKELLRYVS EDAPILPEPN SVPQQYQPCL PEVACLDDPV QEPNKSMFEK TKFGQGTSRE SMQSSPRYLQ INEILLISDQ EFLPCHIMDQ HWKFCVECEE LTP

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with ANKRD31?

The strongest Open Targets associations for ANKRD31 are genetic non-acquired premature ovarian failure, low density lipoprotein cholesterol measurement, apolipoprotein B measurement, neurodegenerative disease and Alzheimer disease.

How long is the ANKRD31 protein?

The Homo sapiens ANKRD31 protein (UniProt Q8N7Z5) is 1873 amino acids long.

Browse: Targets: A · all protein targets A–Z · drugs A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Explore Ankyrin repeat domain-containing protein 31 with MolForge

Find binders, run structure-based screening, and map this target across diseases and approved drugs with our AI-powered platform.

Browse all targets

Quick facts

UniProtQ8N7Z5
GeneANKRD31
OrganismHomo sapiens
Length1873
Binders0
Diseases120
View on UniProt